Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tan, Amanda C
VALOR, NCT05953090: Vaginal Atrophy & Long-term Observation of Recovery	Recruiting	N/A	2000	US	7-0940, StrataMGT	Stratpharma AG	Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)	06/26	12/26
Nguyen, Diana
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
REVERSE-HF, NCT05318105: Ultrafiltration Versus IV Diuretics in Worsening Heart Failure	Recruiting	N/A	372	US	Aquadex Smartflow® System, IV Loop Diuretics	Nuwellis, Inc.	Heart Failure (for Example, Fluid Overload)	07/25	10/25
VALOR, NCT05953090: Vaginal Atrophy & Long-term Observation of Recovery	Recruiting	N/A	2000	US	7-0940, StrataMGT	Stratpharma AG	Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)	06/26	12/26